You are here: Industry Insights > Argenx

News List

Argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in The Lancet Neurology firstwordpharma
June 17, 2021
argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG).
Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab americanpharmaceuticalreview
June 09, 2021
Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision to discontinue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets ...
Elektrofi, Argenx Enter Collaboration and License Agreement contractpharma
April 28, 2021
Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, has entered into a collaboration and license agreement with argenx to explore new subcutaneous formulations for therapeutic products directed at the ...
Halozyme Announces argenx Has Selected Second Target under ENHANZE® Technology Collaboration, License Agreement americanpharmaceuticalreview
May 23, 2019
Halozyme Therapeutics announced argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.
Argenx to leverage Halozyme’s subcutaneous drug delivery technology pharmaceutical-technology
February 19, 2019
Dutch biotechnology company Argenx has signed a global collaboration and licence agreement to leverage US-based Halozyme Therapeutics’ drug delivery technology ENHANZE....
Johnson & Johnson pays $300m to develop cusatuzumab pharmatimes
December 07, 2018
Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies.
Janssen affiliate Cilag and Argenx sign deal for cancer therapy pharmaceutical-technology
December 05, 2018
Janssen Pharmaceutical affiliate Cilag International has signed a global collaboration and license agreement with Dutch biotechnology company Argenx for cusatuzumab (ARGX-110)....
Johnson & Johnson pays $300 million upfront under deal to develop argenx's cancer drug cusatuzumab firstwordpharma
December 03, 2018
Johnson & Johnson's Janssen Pharmaceutical unit entered an agreement potentially worth up to $1.6 billion to develop and market argenx's cusatuzumab in a number of cancers, including haematological malignancies, the companies announced Monday.
Racing UCB and Roivant, Argenx clears phase 2 in primary immune thrombocytopenia fiercebiotech
September 18, 2018
A phase 3 trial, plus a phase 2 assessment of a subcutaneous formulation, are now in the works.
AbbVie licenses GARP checkpoint inhibitor from Argenx fiercebiotech
August 23, 2018
AbbVie has taken up its option to license an immune checkpoint inhibitor from Argenx. The dealgives AbbVie the global rights to an anti-GARP antibody designed to block the immunosuppressive activity of regulatory T cells (Tregs).

Previous page 1 2 Next page